<DOC>
	<DOCNO>NCT00353665</DOCNO>
	<brief_summary>The purpose trial study effect Memantine ( uncompetitive , moderate affinity , NMDA receptor antagonist bind NMDA receptor channel , regulate calcium influx neuron ) , drug use treat AlzheimerÂ´s disease , progression Amyotrophic Lateral Sclerosis ( ALS ) . Memantine add riluzole ( single drug approve treat ALS ) .</brief_summary>
	<brief_title>Memantine Disability Amyotrophic Lateral Sclerosis ( MEDALS )</brief_title>
	<detailed_description>Phase 2/3 trial ALS patient Double-blinded , parallel , randomize ( 2 bloc , bulbar/spinal onset ) Memantine + riluzole x Placebo + Memantine Inclusion criterion : - &lt; 75 year disease onset - &lt; 3 year disease progression - ALS-FRS &gt; 24 - FVC &gt; 60 - Probable definite disease ( revise El Escorial criterion ) - No medical condition - Normal blood test - Regular medication riluzole &gt; 1 month - Nerve conduction study rule conduction block - EMG widespread loss motor unit ( revise El Escorial criterion ) - At least one hand ADM strength &gt; 2 MRC scale Duration - 2 year Evaluation - every 3 month Primary outcome - ALS-FRS Secondary -SF36 , Hamilton depression scale , motor unit number estimation , neurophysiological index , strength ( clinical evaluation ) ; side-effects Intention treat analysis 60 patient number estimate 50 % change decline rate ALS-FRS</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Definite probable disease revise El Escorial criterion Normal blood test Riluzole treatment 1 month EMG accordance El Escorial criterion Other disease ( PNP ) Both ADM muscle &lt; 3 MRC scale Conduction block nerve conduction test Disease duration &gt; 3 year ALSFRS &lt; 25 Forced vital capacity &lt; 60 %</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>motor neuron disease</keyword>
	<keyword>memantine</keyword>
	<keyword>clinical trial</keyword>
</DOC>